The m6A regulator KIAA1429 stabilizes RAB27B mRNA and promotes the progression of chronic myeloid leukemia and resistance to targeted therapy

KIAA1429-driven m6A modification promotes #ChronicMyeloidLeukemia progression and imatinib resistance via the m6A/YTHDF1–RAB27B axis, while #rucaparib suppresses KIAA1429, reduces #TumorGrowth, and enhances imatinib sensitivity.
#OpenAccess: doi.org/10.1016/j.ge...

The phase 3 ARIEL4 trial to evaluate #rucaparib vs. standard-of-care #chemotherapy in patients with relapsed #BRCA-mutated #ovariancancer showed median overall survival in the rucaparib group was 19.4 months vs. 25.4 months in the chemotherapy group.
www.thelancet.com/journals/lan...